Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $6.50

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.50.

A number of analysts recently issued reports on REPL shares. Cantor Fitzgerald upgraded Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. Leerink Partners reaffirmed a “market perform” rating and set a $3.00 target price (down previously from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Leerink Partnrs cut Replimune Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 22nd. BMO Capital Markets lowered shares of Replimune Group from an “outperform” rating to an “underperform” rating and cut their price objective for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $9.00 price objective (down previously from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd.

Replimune Group Stock Up 2.9%

REPL opened at $5.99 on Monday. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a market cap of $467.58 million, a PE ratio of -1.85 and a beta of 0.51. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21. The company has a 50 day moving average of $6.82 and a 200 day moving average of $8.58.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). On average, sell-side analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insider Activity at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its stake in Replimune Group by 26,006.0% in the 2nd quarter. Osaic Holdings Inc. now owns 26,106 shares of the company’s stock worth $243,000 after acquiring an additional 26,006 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of Replimune Group by 394.0% during the 2nd quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after acquiring an additional 54,178 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Replimune Group by 2,020.8% during the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after purchasing an additional 9,235 shares in the last quarter. Exome Asset Management LLC increased its position in shares of Replimune Group by 34.9% in the second quarter. Exome Asset Management LLC now owns 397,846 shares of the company’s stock worth $3,696,000 after purchasing an additional 103,000 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Replimune Group in the second quarter valued at approximately $125,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.